MX2018010032A - Formulaciones de antagonista de il-6 y sus usos. - Google Patents
Formulaciones de antagonista de il-6 y sus usos.Info
- Publication number
- MX2018010032A MX2018010032A MX2018010032A MX2018010032A MX2018010032A MX 2018010032 A MX2018010032 A MX 2018010032A MX 2018010032 A MX2018010032 A MX 2018010032A MX 2018010032 A MX2018010032 A MX 2018010032A MX 2018010032 A MX2018010032 A MX 2018010032A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- antagonist
- formulations
- antagonist formulations
- featured
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 101150101999 IL6 gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004889 Interleukin-6 Human genes 0.000 abstract 5
- 108090001005 Interleukin-6 Proteins 0.000 abstract 5
- 229940100601 interleukin-6 Drugs 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298774P | 2016-02-23 | 2016-02-23 | |
| PCT/US2017/019131 WO2017147293A1 (en) | 2016-02-23 | 2017-02-23 | Il-6 antagonist formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018010032A true MX2018010032A (es) | 2019-03-11 |
Family
ID=59685584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010032A MX2018010032A (es) | 2016-02-23 | 2017-02-23 | Formulaciones de antagonista de il-6 y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190046642A1 (OSRAM) |
| EP (1) | EP3419599A4 (OSRAM) |
| JP (2) | JP2019510078A (OSRAM) |
| KR (1) | KR20180116359A (OSRAM) |
| CN (1) | CN108718522A (OSRAM) |
| AR (1) | AR107708A1 (OSRAM) |
| AU (1) | AU2017223687A1 (OSRAM) |
| BR (1) | BR112018017031A2 (OSRAM) |
| CA (1) | CA3012350A1 (OSRAM) |
| MX (1) | MX2018010032A (OSRAM) |
| WO (1) | WO2017147293A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200093628A (ko) * | 2017-11-30 | 2020-08-05 | 바이오-테라 솔루션즈 리미티드 | Il-6 관련 질병을 치료하는 인간화항체의 액체 제제 |
| JP7407723B2 (ja) * | 2018-09-14 | 2024-01-04 | 田辺三菱製薬株式会社 | ヒト抗ｉｌ－３３モノクローナル抗体含有医薬用組成物 |
| US12433948B2 (en) | 2018-10-31 | 2025-10-07 | Richter Gedeon Nyrt | Aqueous pharmaceutical formulations |
| EP3962942B1 (en) * | 2019-05-01 | 2025-10-22 | Novo Nordisk A/S | Anti-il-6 antibody formulation |
| KR20220143923A (ko) * | 2020-02-21 | 2022-10-25 | 스핏파이어 파마, 엘엘씨 | Glp-1r 및 gcgr 효능제, 제형 및 사용 방법 |
| RU2745814C1 (ru) * | 2020-06-05 | 2021-04-01 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция левилимаба и ее применение |
| CN116710568A (zh) * | 2020-06-26 | 2023-09-05 | 特里福伊尔治疗公司 | 重组修饰成纤维细胞生长因子及其治疗用途 |
| WO2022026914A1 (en) * | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| CN116261448A (zh) * | 2020-08-19 | 2023-06-13 | 百奥泰生物制药股份有限公司 | 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂 |
| KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
| US20230073821A1 (en) * | 2021-08-27 | 2023-03-09 | International Business Machines Corporation | Antigen-binding proteins targeting coronavirus (cov) variants |
| JP2023042974A (ja) * | 2021-09-15 | 2023-03-28 | シスメックス株式会社 | 抗サイトカイン抗体の抗原に対する親和性を向上させる方法、抗サイトカイン抗体の製造方法及び抗サイトカイン抗体 |
| CN116355825A (zh) * | 2022-02-25 | 2023-06-30 | 南京工业大学 | 一种强化纤维素合成来提高人表皮生长因子分泌生产效率的方法 |
| JP2025534333A (ja) * | 2022-09-30 | 2025-10-15 | ソネット バイオセラピューティクス，インコーポレイテッド | 低用量ｉｌ－６製剤およびその使用方法 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| ES2287206T3 (es) | 1991-03-01 | 2007-12-16 | Dyax Corporation | Proceso para el desarrollo de mini-proteinas de union. |
| WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
| EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
| US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| WO2003094888A1 (en) | 2002-05-07 | 2003-11-20 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| WO2004045507A2 (en) | 2002-11-15 | 2004-06-03 | Centocor, Inc. | Anti-angiogenic uses of il-6 antagonists |
| US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| CA2551097A1 (en) | 2003-12-23 | 2005-07-14 | Rinat Neuroscience Corp. | Agonist anti-trkc antibodies and methods using same |
| CN101001873B (zh) | 2004-08-04 | 2013-03-13 | 曼璀克生物科技有限责任公司 | Fc区变体 |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2007076927A1 (en) | 2005-12-30 | 2007-07-12 | Merck Patent Gmbh | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| JP2009529339A (ja) | 2006-03-13 | 2009-08-20 | アブリンクス エン．ヴェー． | Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド |
| NZ572807A (en) | 2006-05-19 | 2011-10-28 | Alder Biopharmaceuticals Inc | Culture method for obtaining a clonal population of antigen-specific b cells |
| CA2675602A1 (en) | 2007-02-16 | 2008-08-21 | Wyeth | Protein formulations containing sorbitol |
| SI3187506T1 (sl) | 2007-05-21 | 2019-08-30 | Alderbio Holdings Llc | Protitelesa proti IL-6 in njihova uporaba |
| JP5503543B2 (ja) * | 2007-09-14 | 2014-05-28 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
| US8043620B2 (en) | 2007-11-21 | 2011-10-25 | Amgen Inc. | Wise binding agents and epitopes |
| US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
| KR20100120289A (ko) | 2008-01-15 | 2010-11-15 | 애보트 게엠베하 운트 콤파니 카게 | 분말상 단백질 조성물 및 이의 제조 방법 |
| MX2011001371A (es) | 2008-08-05 | 2011-06-16 | Novartis Ag | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5. |
| PT2324930E (pt) | 2008-09-12 | 2012-12-27 | Kdf Co Ltd | Aparelho para criar jorros de água |
| US20120005773A1 (en) * | 2008-10-01 | 2012-01-05 | Aasen Eric D | Transgenic plants with enhanced agronomic traits |
| US8992920B2 (en) * | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| CN102224169A (zh) | 2008-11-26 | 2011-10-19 | 葛兰素集团有限公司 | 多肽、抗体可变结构域和拮抗剂 |
| EP2391384A4 (en) * | 2009-01-29 | 2012-12-26 | Medimmune Llc | HUMAN ANTI-IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-TIME AND USE THEREOF FOR TREATMENTS IN ONCOLOGY AND FOR AUTOIMMUNE AND IGNITION |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| PH12013500070A1 (en) | 2010-07-12 | 2017-08-23 | Covx Tech Ireland Ltd | Multifunctional antibody conjugates |
| MX2014006673A (es) | 2011-12-07 | 2014-09-04 | Amgen Inc | Separacion de la isoforma de disulfuro de la igg2. |
| KR20150033620A (ko) | 2012-06-01 | 2015-04-01 | 옵쏘테크 코포레이션 | 항-pdgf 압타머 및 vegf 길항제를 포함하는 조성물 |
| MX361337B (es) | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| PE20191815A1 (es) | 2012-09-07 | 2019-12-27 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| MX2015004668A (es) * | 2012-10-25 | 2015-07-23 | Medimmune Llc | Formulacion estable de anticuerpos de baja viscosidad. |
| KR102149206B1 (ko) | 2012-11-08 | 2020-08-31 | 세센 바이오, 아이엔씨. | 인터루킨-6의 길항제 및 이의 용도 |
| IL294463A (en) * | 2013-07-12 | 2022-09-01 | Iveric Bio Inc | Methods for treating or preventing eye conditions |
| EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| EP4268843B1 (en) * | 2014-11-07 | 2025-09-03 | F. Hoffmann-La Roche Ltd | Improved il-6 antibodies |
| WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2017
- 2017-02-23 AR ARP170100456A patent/AR107708A1/es unknown
- 2017-02-23 EP EP17757207.0A patent/EP3419599A4/en active Pending
- 2017-02-23 CA CA3012350A patent/CA3012350A1/en not_active Abandoned
- 2017-02-23 MX MX2018010032A patent/MX2018010032A/es unknown
- 2017-02-23 WO PCT/US2017/019131 patent/WO2017147293A1/en not_active Ceased
- 2017-02-23 JP JP2018563405A patent/JP2019510078A/ja active Pending
- 2017-02-23 BR BR112018017031A patent/BR112018017031A2/pt not_active IP Right Cessation
- 2017-02-23 US US16/078,671 patent/US20190046642A1/en not_active Abandoned
- 2017-02-23 KR KR1020187027338A patent/KR20180116359A/ko not_active Withdrawn
- 2017-02-23 AU AU2017223687A patent/AU2017223687A1/en not_active Abandoned
- 2017-02-23 CN CN201780013039.9A patent/CN108718522A/zh active Pending
-
2021
- 2021-08-31 US US17/462,654 patent/US12048746B2/en active Active
-
2022
- 2022-03-31 JP JP2022058898A patent/JP2022084922A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12048746B2 (en) | 2024-07-30 |
| AR107708A1 (es) | 2018-05-23 |
| US20190046642A1 (en) | 2019-02-14 |
| WO2017147293A1 (en) | 2017-08-31 |
| US20220241414A1 (en) | 2022-08-04 |
| AU2017223687A1 (en) | 2018-08-09 |
| JP2022084922A (ja) | 2022-06-07 |
| EP3419599A4 (en) | 2019-09-11 |
| BR112018017031A2 (pt) | 2019-01-22 |
| CN108718522A (zh) | 2018-10-30 |
| KR20180116359A (ko) | 2018-10-24 |
| CA3012350A1 (en) | 2017-08-31 |
| JP2019510078A (ja) | 2019-04-11 |
| EP3419599A1 (en) | 2019-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010032A (es) | Formulaciones de antagonista de il-6 y sus usos. | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX375752B (es) | Inhibidores de tirosina quinasa de bruton. | |
| CL2019000245A1 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
| MX378566B (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| JOP20200230A1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| MX383650B (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| MX385336B (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| MX386938B (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
| MX383292B (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
| CO2018012506A2 (es) | Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| MX2017013564A (es) | Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual. |